Stellar(US) | $2,700,000 | (Jan 9, 2025)
XyloCor Therapeutics, Inc. | $67,500,000 | (Jan 9, 2025)
Aspect Biosystems | $115,000,000 | (Jan 9, 2025)
Certified by Founder
Lodge
Tenvie Therapeutics
start up
United States
- South San Francisco, California
- 09/01/2025
- Unknown
- $200,000,000
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
- Industry Biotechnology Research
- Website https://tenvie.com/
- LinkedIn https://www.linkedin.com/company/tenvie-therapeutics/
Relief Cardiovascular | $12,000,000 | (Jan 9, 2025)
VitVio | $2,000,000 | (Jan 9, 2025)
Qualified Health | $30,000,000 | (Jan 9, 2025)
Evergreen Nephrology | $130,000,000 | (Jan 9, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)
Deep Vector | $1,500,000 | (Jan 9, 2025)
Ubiety Technologies, Inc. | $10,000,000 | (Jan 9, 2025)